Oppenheimer Reiterates Outperform on Pharming, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the price target from $42 to $41.